Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $295.2 million.

  • Sutro Biopharma's Total Non-Current Liabilities fell 1288.98% to $295.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.2 million, marking a year-over-year decrease of 1288.98%. This contributed to the annual value of $340.9 million for FY2024, which is 673.75% up from last year.
  • As of Q3 2025, Sutro Biopharma's Total Non-Current Liabilities stood at $295.2 million, which was down 1288.98% from $292.8 million recorded in Q2 2025.
  • Sutro Biopharma's Total Non-Current Liabilities' 5-year high stood at $345.5 million during Q1 2025, with a 5-year trough of $50.6 million in Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $241.3 million (2022), whereas its average is $216.8 million.
  • As far as peak fluctuations go, Sutro Biopharma's Total Non-Current Liabilities plummeted by 2944.49% in 2021, and later skyrocketed by 24293.6% in 2022.
  • Over the past 5 years, Sutro Biopharma's Total Non-Current Liabilities (Quarter) stood at $88.7 million in 2021, then soared by 113.96% to $189.8 million in 2022, then surged by 68.3% to $319.4 million in 2023, then rose by 6.74% to $340.9 million in 2024, then fell by 13.4% to $295.2 million in 2025.
  • Its last three reported values are $295.2 million in Q3 2025, $292.8 million for Q2 2025, and $345.5 million during Q1 2025.